Journal of Psoriasis and Psoriatic Arthritis最新文献_第9页

The Role of Pain in the Lives of Patients with Psoriasis: A Qualitative Study on an Inadequately Addressed Symptom. 疼痛在牛皮癣患者生活中的作用:一项对未充分解决症状的定性研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-12-12 DOI: 10.1177/24755303211066928

Ashley M Snyder, Vanina L Taliercio, Lisa B Webber, Adelheid U Brandenberger, Bianca E Rich, Abram P Beshay, Joshua E Biber, Rachel Hess, Jamie L W Rhoads, Aaron M Secrest

{"title":"The Role of Pain in the Lives of Patients with Psoriasis: A Qualitative Study on an Inadequately Addressed Symptom.","authors":"Ashley M Snyder, Vanina L Taliercio, Lisa B Webber, Adelheid U Brandenberger, Bianca E Rich, Abram P Beshay, Joshua E Biber, Rachel Hess, Jamie L W Rhoads, Aaron M Secrest","doi":"10.1177/24755303211066928","DOIUrl":"10.1177/24755303211066928","url":null,"abstract":"Background: Patients with psoriasis commonly report experiencing severe sensory symptoms, and the burden of these symptoms can extend beyond unpleasant experiences to impair patients' health-related quality of life (HRQL). However, the symptom of pain and its consequences are still poorly understood in psoriasis patients. Objective: To understand the quality and intensity of pain associated with psoriasis as well as its interference with daily function in patients with psoriasis. Methods: Three focus groups and four interviews with psoriasis patients were conducted (n = 25). A trained facilitator used a semi-structured interview guide based on a literature review and a theory-driven approach. Two researchers independently coded the narratives and reached a consensus on the major themes using NVivo 12 software. Results: Our analysis produced five main themes regarding pain. (1) Perception of pain was illustrated through intense descriptors. (2) Patients identified pain triggers, including self-inflicted triggers. (3) Patients found coping strategies to deal with pain, including suppression of sensory experience. (4) Emotional suffering was linked primarily to the compulsion to continue scratching despite repeated efforts to stop and the failure of physicians to acknowledge the burden of the pain, which led to inadequate pain management. (5) Pain led to an overt impact on HRQL in these patients through interference with daily activity, intimate relationships, and sleep. Conclusions: Pain can be a significant hardship for patients with psoriasis. We encourage clinicians to inquire about pain separate from pruritus and to consider HRQL impacts of their patients' pain when determining treatments.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"29-34"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42235930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study. 医疗保健提供者在治疗牛皮癣患者时面临许多挑战:一项混合方法研究的结果

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-12-07 DOI: 10.1177/24755303211062887

Suzanne Murray, Jeffrey Crowley, Melinda J Gooderham, Alan Kivitz, Vinod Chandran, Sophie Péloquin, Paul P Doghramji, Christie Freeman, Patrice Lazure

{"title":"Healthcare Providers Face Numerous Challenges in Treating Patients with Psoriasis: Results from a Mixed-Methods Study.","authors":"Suzanne Murray, Jeffrey Crowley, Melinda J Gooderham, Alan Kivitz, Vinod Chandran, Sophie Péloquin, Paul P Doghramji, Christie Freeman, Patrice Lazure","doi":"10.1177/24755303211062887","DOIUrl":"10.1177/24755303211062887","url":null,"abstract":"Background: The paradigm shift toward biologic medications in psoriasis care requires healthcare providers (HCPs) to become acquainted with mechanisms of action and safety profiles of these new treatments to confidently use them in practice. A better understanding of this paradigm shift is necessary to provide adequate education for HCPs in psoriasis care.Objectives: This study assessed clinical practice gaps and challenges experienced by HCPs caring for patients with psoriasis.Methods: A mixed-methods approach was used to identify practice gaps and clinical challenges of dermatologists, rheumatologists, primary care physicians, physician assistants, and nurse practitioners with various levels of clinical experience in academic and community-based settings. Qualitative and quantitative data were collected sequentially. Interviews were transcribed and thematically analyzed.Results: A total of 380 psoriasis care providers in Canada and the US participated in this study. Analysis revealed challenges in establishing an accurate diagnosis of psoriasis (including screening for sub-type and distinguishing psoriasis from other skin conditions), selecting treatment (particularly regarding recently approved treatments), monitoring side effects, and collaborating with other HCPs involved in psoriasis care.Conclusion: These findings highlight educational needs of HCPs involved in psoriasis care that could have repercussions on accurate and timely diagnosis of the condition, treatment initiation, side effect monitoring, and continuity of care. Findings provide a starting point for clinicians to reflect on their practice and for the improvement of continuing professional development interventions that would bridge these gaps.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"35-43"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48261528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey. 牛皮癣患者接种新冠肺炎疫苗的可能性：来自世界大型调查的结果

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-12-10 DOI: 10.1177/24755303211067822

George C Gondo, Megan H Noe, Stacie J Bell, Christopher T Ritchlin

{"title":"Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.","authors":"George C Gondo, Megan H Noe, Stacie J Bell, Christopher T Ritchlin","doi":"10.1177/24755303211067822","DOIUrl":"10.1177/24755303211067822","url":null,"abstract":"Introduction: Development and dissemination of novel COVID-19 vaccines represent an opportunity to end the COVID-19 pandemic by vaccinating an estimated 80% of the population. Objectives: This study examines perceptions, and demographic and clinical factors influencing the likelihood of adults with psoriasis receiving a novel COVID-19 vaccine. Methods: A cross sectional study conducted from October-November 2020 of 1405 adults with psoriatic disease with prior contact to a patient advocacy organization. The main outcome of interest was the likelihood of receiving a COVID-19 vaccine. Chi-square tests and logistic regression examined the relationship between individual characteristics and likelihood of receiving a COVID-19 vaccine. Results: Most participants (65%) received a flu vaccination in the last 12 months and were (64.2%) likely to receive a COVID-19 vaccine, while 35.9% reported being unlikely receive a vaccine. Likelihood of COVID-19 vaccination was associated with receiving the flu vaccine, race, ethnicity, sex, BMI, age, income, severity of PsO and PsA. When controlling for ethnicity, race, male sex, overweight/obese status, age, biologic use, disease type, comorbidities linked with worse COVID-19 outcomes, PsA symptoms, and skin disease severity, individuals who received the flu vaccine and those with annual household income over $75,000 were most likely to receive a COVID-19 vaccine. Conclusions: Vaccine hesitancy among individuals with psoriatic disease is considerable. Dermatologists and rheumatologists can increase COVID-19 vaccine uptake by actively engaging their patients on this topic using guidance published by the National Psoriasis Foundation on the management of psoriatic disease during the COVID-19 pandemic.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"17-23"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49063133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re-Classification of Psoriasis Severity: Perspectives and Controversy. 银屑病严重程度的重新分类：观点与争议

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2022-01-18 DOI: 10.1177/24755303211071033

Danielle Yee, April W Armstrong

引用次数: 0

A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis. 用Secukinumab治疗活动性银屑病关节炎患者后，Ixekizumab疗效的回顾性研究

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-12-20 DOI: 10.1177/24755303211063841

Saman Darabian, Maziar Badii, Jan P Dutz, Jonathan Chan

{"title":"A Retrospective Study on the Effectiveness of Ixekizumab After Treatment With Secukinumab for Patients With Active Psoriatic Arthritis.","authors":"Saman Darabian, Maziar Badii, Jan P Dutz, Jonathan Chan","doi":"10.1177/24755303211063841","DOIUrl":"10.1177/24755303211063841","url":null,"abstract":"Objectives: This study aims to evaluate clinical responses in patients with active psoriatic arthritis who, despite secukinumab 300 mg subcutaneous monthly, are switched to ixekizumab 80 mg subcutaneous every four weeks. Methods: We conducted a chart review of adult patients with psoriatic arthritis treated at one clinical center. We identified all patients with active inflammatory arthritis who were switched from secukinumab to ixekizumab. Baseline demographics such as disease duration, age, gender, number of previous DMARDs, and previous time on secukinumab were collected. We collected clinical outcome data such as tender and swollen joint count, enthesitis based on SPARCC score, dactylitis, psoriasis severity, CRP, and BASDAI if axial involvement was present. Results: Eight of 10 patients were included in the analysis. Most patients were female, average age 62 years old, and had been on secukinumab for an average of 79 weeks. Twelve weeks following switch to ixekizumab, 6/8 had improvement in tender joint count, 6/8 improved in swollen joint count, 2/2 had resolution of enthesitis, 4/4 had resolution of dactylitis, 5/6 had improvement in psoriasis severity, 1 patient had absolute improvement of 2.3 in BASDAI, and 7/8 had improvement in the CRP level. Conclusions: Patients with active psoriatic arthritis despite treatment with secukinumab may still have a clinical response following treatment with another anti-IL17 agent. Larger studies will be required to confirm this finding, and studies which emphasize dactylitis and enthesitis outcomes will be needed as most patients did not have activity in these domains.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"13-16"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47829748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2021 Reviewer Thank You. 2021评审员谢谢

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2022-01-18 DOI: 10.1177/24755303221075217

引用次数: 0

Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis. 白细胞介素-36受体拮抗剂突变携带者与泛发性脓疱型银屑病的急性呼吸窘迫综合征。

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-12-10 DOI: 10.1177/24755303211051724

Avital Baniel, Efrat Bar-Ilan, Yuval Hilerowicz, Ilan Merdler, Eden Shkury, Ofer Sarig, Marina Eskin-Schwartz, Eli Sprecher

{"title":"Acute Respiratory Distress Syndrome in a Carrier of an Interleukin-36 Receptor Antagonist Mutation With Generalized Pustular Psoriasis.","authors":"Avital Baniel, Efrat Bar-Ilan, Yuval Hilerowicz, Ilan Merdler, Eden Shkury, Ofer Sarig, Marina Eskin-Schwartz, Eli Sprecher","doi":"10.1177/24755303211051724","DOIUrl":"https://doi.org/10.1177/24755303211051724","url":null,"abstract":"Background: Generalized pustular psoriasis of von Zumbusch is a rare variant of psoriasis often accompanied by systemic, sometimes life-threatening, symptoms. Generalized pustular psoriasis sometimes arises in pregnancy.Case report: A 31-year-old female, with a history of schizophrenia and recurrent episodes of gestation-associated pustular psoriasis, was admitted to our department because of a generalized pustular rash during the 22nd week of her fifth pregnancy. Clinical and histopathological examinations were suggestive of generalized pustular psoriasis (von Zumbusch type). During this hospitalization, she developed acute dyspnea, fever, tachycardia, and marked leukocytosis. An extensive workup failed to reveal an infectious, cardiac, or pulmonary abnormality, while severe respiratory distress necessitated mechanical ventilation. Radio-imaging revealed diffuse alveolar infiltrates consistent with acute respiratory distress syndrome (ARDS). In the absence of any other plausible cause, ARDS was considered as secondary to her skin disease. Genetic base was suspected, and genetic analysis uncovered a novel mutation in IL36RN encoding the IL-36 receptor antagonist. Only 15 cases of ARDS secondary to psoriasis have been described to date. This is the first report of this very rare complication in a known carrier of an IL36RN mutation. The fact that IL36RN is abundantly expressed in the lung as well as in the epidermis may underlie the unusual clinical features of this dramatic case.Conclusion: The present case suggests the need to carefully monitor patients with pregnancy-associated generalized pustular psoriasis for possible life-threatening pulmonary complications and the possible link to IL36RN mutation.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"9-12"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142297485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients. 免疫调节剂治疗的银屑病患者对BNT162b2疫苗的抗体反应

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2022-01-01 Epub Date: 2021-11-12 DOI: 10.1177/24755303211056059

Felix Pavlotsky, Zvi Segal, Aviv Barzilai

{"title":"Antibody Response to BNT162b2 Vaccine in Immune Modifiers-Treated Psoriatic Patients.","authors":"Felix Pavlotsky, Zvi Segal, Aviv Barzilai","doi":"10.1177/24755303211056059","DOIUrl":"10.1177/24755303211056059","url":null,"abstract":"Background: Data regarding anti-COVID-19 vaccination efficacy in psoriasis patients treated with immune-modulatory medications are scarce.Objective: This study aims to examine the rate of positive antibody response following BNT162b2 vaccine in those patients.Methods: BNT162b2-vaccinated and immune modifier-treated psoriatic patients were assigned to serological testing of IgG antibodies to protein S of SARS-CoV-2 after the second vaccination dose by Abbott Architect or Beckman Coulter. Levels ≥ 1 S1 units/mL (S/ml) and > 150 arbitrary units/ml (AU/ml) are considered a positive antibody response, respectively. The antibody levels further analyzed according to the patient's characteristics and compared to health workers' controls.Results: Forty-nine of the 51 patients had a positive antibody response. Overall, patients treated with immune-modulatory medications had antibody levels similar to the control group.Conclusions: Immune modifier-treated psoriasis patients seem to develop a positive antibody response to the full BNT162b2 vaccination in the vast majority of cases.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"7 1","pages":"24-28"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42104365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GRAPPA 2021 Virtual Annual Meeting and Trainee Symposium, July 8-10, 2021 Trainee Abstracts GRAPPA 2021虚拟年会和学员研讨会，2021年7月8日至10日学员摘要

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2021-10-01 DOI: 10.1177/24755303211043841

引用次数: 1

Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline. 利用基于遗传学的优先索引管道识别新的银屑病药物靶点。

Journal of Psoriasis and Psoriatic Arthritis Pub Date : 2021-10-01 Epub Date: 2021-06-21 DOI: 10.1177/24755303211026023

Audrey Bui, Jared Liu, Julie Hong, Edward Hadeler, Megan Mosca, Nicholas Brownstone, Wilson Liao

{"title":"Identifying Novel Psoriatic Disease Drug Targets Using a Genetics-Based Priority Index Pipeline.","authors":"Audrey Bui, Jared Liu, Julie Hong, Edward Hadeler, Megan Mosca, Nicholas Brownstone, Wilson Liao","doi":"10.1177/24755303211026023","DOIUrl":"https://doi.org/10.1177/24755303211026023","url":null,"abstract":"Background: Despite numerous genome-wide association studies conducted in psoriasis and psoriatic arthritis, only a small fraction of the identified genes has been therapeutically targeted.Objective: We sought to identify and analyze potential therapeutic targets for psoriasis and psoriatic arthritis (PsA) using the priority index (Pi), a genetics-dependent drug target prioritization approach.Methods: Significant genetic variants from GWAS for psoriasis, PsA, and combined psoriatic disease were annotated and run through the Pi pipeline. Potential drug targets were identified based on genomic predictors, annotation predictors, pathway enrichment, and pathway crosstalk.Results: Several gene targets were identified for psoriasis and PsA that demonstrated biological associations to their respective diseases. Some are currently being explored as potential therapeutic targets (i.e. ICAM1, NF-kB, REV3L, ADRA1B for psoriasis; CCL11 for PsA); others have not yet been investigated (i.e. LNPEP, LCE3 for psoriasis; UBLCP1 for PsA). Additionally, many nodal points of potential intervention were identified as promising therapeutic targets. Of these, some are currently being studied such as TYK2 for psoriasis, and others have yet to be explored (i.e. PPP2CA, YAP1, PI3K, AKT, FOXO1, RELA, CSF2, IFNGR1, IFNGR2 for psoriasis; GNAQ, PLCB1, GNAI2 for PsA).Conclusion: Through Pi, we identified data-driven candidate therapeutic gene targets and pathways for psoriasis and PsA. Given the sparse PsA specific genetic studies and PsA specific drug targets, this analysis could prove to be particularly valuable in the pipeline for novel psoriatic therapies.","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":"6 4","pages":"185-197"},"PeriodicalIF":0.0,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/24755303211026023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40399672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6